Analyst Summary:
Curis, a biotechnology company focusing on the development of innovative therapeutics for the treatment of cancer, has reported its Q4 2022 financial results. The company has focused its resources on developing emavusertib and announced that it has completed enrolment of 9 additional patients requested by the FDA ahead of schedule in its TakeAim Leukemia study. The company expects to collect data from these patients in Q2 and request a Q3 meeting to discuss the same with the FDA. James Dentzer, President and CEO of Curis, stated, "This is an important step towards resolving the partial clinical hold in the TakeAim Leukemia study". The company's cash and cash equivalents and investments are expected to enable it to maintain its planned operations through 2025. The conference call discussed Curis's update on the ongoing clinical take aim leukemia trial and also CURIS's financial results. The company's net loss for 2022 was $31.5 million, or $0.28 per share on both a basic and diluted basis compared to a loss of $43.9 million. The company's management predicts that the enrollment completion is a crucial step in resolving the partial clinical hold in the TakeAim Leukemia study.